Anti-Yellow Fever Virus, NS1 (YFV-0715)

Anti-Yellow Fever Virus, NS1 (YFV-0715)

Product No.: Y102

- -
- -
Clone
YFV-0715
Target
NS1
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
Non-structural protein 1, NS1
Isotype
Mouse IgG1
Applications
ELISA

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactivity Species
Yellow Fever Virus
Host Species
Mouse
Product Concentration
≥1.0 mg/ml
Purity
≥90%
Formulation
Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
This monoclonal antibody is purified by protein A chromatography or sequential differential precipitations.
Storage and Handling
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2-8°C Wet Ice
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA: 1:20-1:200
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Anti-Yellow Fever Virus (Clone YFV-0715) is specific for NS1 of Yellow Fever Virus and does not cross-react with related viruses including West Nile Virus, Japanese Encephalitis Virus, and Tick-Borne Encephalitis Virus.
Matched Pair
Best ELISA pair (capture/detection), YFV-0715/YFV-8007
Background
Yellow Fever Virus (YFV) is a single-stranded RNA virus belonging to the Flaviviridae family. It is transmitted to humans primarily through the bites of infected mosquitoes, particularly Aedes aegypti and Aedes albopictus. Yellow Fever has been a significant public health concern for centuries, causing periodic outbreaks and devastating epidemics in tropical regions of Africa and the Americas. The virus is responsible for a wide range of clinical manifestations, from asymptomatic or mild febrile illness to severe hemorrhagic fever and organ failure, which can be fatal. The disease is named for the jaundice that can occur in severe cases due to liver involvement. Yellow Fever vaccines have been highly effective in preventing the disease, and mass vaccination campaigns have played a crucial role in controlling outbreaks. However, Yellow Fever remains a global health threat, particularly in areas where vaccination coverage is low or lacking. Ongoing surveillance, mosquito control measures, and access to vaccination are essential components of the efforts to prevent and control Yellow Fever.

NS1 (Non-Structural Protein 1) plays an important role in the viral life cycle and interacts with the host immune system aiding in immune evasion. NS1 has been investigated as a potential diagnostic marker for yellow fever infection, as it can be detected in patient samples.

Antigen Details

Research Area
Category B Pathogens
.
Infectious Disease
.
Matched Pair
.
Viral
.
IVD Raw Material

References & Citations

1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD). Link
Indirect Elisa Protocol

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.